An open label, single institution, phase II study of the mTOR inhibitor temsirolimus in unresectable and/or metastatic renal cell carcinoma (RCC) in patients previously treated with both cytokines and one ore more tyrosine kinase inhibitor, The TeRCC study - ND
- Conditions
- renal cell carcinomaMedDRA version: 9.1Level: LLTClassification code 10050513Term: Metastatic renal cell carcinoma
- Registration Number
- EUCTR2007-007045-12-IT
- Lead Sponsor
- OSPEDALE POLICLINICO S. MATTEO
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- Not specified
age >/= 18 years, cyto-hystological diagnosis of renal cell carcinoma, previous treatment with both cytokines and one or more kinase inhibitors, measurable disease, ...
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Major surgical procedure within 28 days prior to study treatment start, other malignancies within the last 5 years, clinically significant cardiovascular disease, myocardial infarction, unstable angina, history of other disease, metabolic disfunction, concomitant radiotherapy in the site of disease, previous radiotherapy or other locoregional antitumoral treatment performed within 21 days before the study recruitment, uncontrolled hyperglicemia, ...
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method